ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2012
Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection.
Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.World journal of gastroenterology · 2017Trial
- The 2024 International Liver Transplant Society and International Liver Cancer Association Consensus Recommendations for Liver Transplantation for Liver Cancer.Liver cancer · 2026Article
- Clinical outcomes of combination therapy for hepatocellular carcinoma in a predominantly hispanic South Texas population.Frontiers in oncology · 2025Article
- Surgical management in hepatocellular carcinoma with portal vein tumour thrombosis: is this the end of the road or a chance to expand the criteria for resectability?Przeglad gastroenterologiczny · 2022Review
- Case Report: Combining liver partition and portal vein ligation after thrombectomy for tumor isolation (CLAPT) to treat advanced hepatocellular carcinoma with portal vein tumor thrombosis.Frontiers in surgery · 2022Article
- Impact of splenomegaly and splenectomy on prognosis in hepatocellular carcinoma with portal vein tumor thrombus treated with hepatectomy.Annals of translational medicine · 2021Article
- Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides.Journal of hepatocellular carcinoma · 2021Review
- A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection.Frontiers in oncology · 2021Article
- Efficiency of regional functional liver volume assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein tumor thrombus.Surgery today · 2020Article
- Article
- Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus.Cancer medicine · 2018Article
- Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus.World journal of hepatology · 2017Review
- New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.Journal of clinical and translational hepatology · 2017Review
- Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges.Oncotarget · 2017Review
- A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection.Oncology letters · 2015Article
- Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein.World journal of hepatology · 2015Review
- Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis.Liver cancer · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe prognosis in patients with hepatocellular carcinoma (HCC) accompanied by main portal vein tumour thrombus (MPVTT) is poor. The aim of this study was to clarify the factors linked to survival of >5 years after hepatectomy in HCC patients with MPVTT.
methodsTwenty-nine HCC patients with MPVTT were divided into two groups comprising, respectively, patients who survived >5 years after hepatectomy (survivors, n= 5) and those who did not (non-survivors, n= 24). The two groups were compared.
resultsOverall survival rates at 1, 3 and 5 years were 62.1%, 24.1% and 17.2%, respectively. Four (80.0%) 5-year survivors had recurrences of HCC in which the number of recurrent nodules was under four. Three (21.4%) of the 14 non-survivors who underwent curative resection experienced recurrences of HCC and all of them demonstrated fewer than four recurrent nodules (P= 0.0114). Local therapy, such as radiofrequency ablation and resection of recurrence, had more often been used in survivors than in non-survivors (P= 0.0364).
conclusionsAlthough surgical outcomes in patients with HCC accompanied by MPVTT are unsatisfactory, some patients do enjoy longterm survival. When the number of recurrent nodules is less than four, local therapy should be selected with the aim of achieving 5-year survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.